OncoMatch/Clinical Trials/NCT07015190

Neoadjuvant Darovasertib in Primary Uveal Melanoma

Is NCT07015190 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies Darovasertib for uveal melanoma.

Phase 3RecruitingIDEAYA BiosciencesNCT07015190Data as of May 2026

Treatment: Darovasertib — This is a Phase 3, randomized, multi-center, open-label study of neoadjuvant darovasertib in subjects with primary non-metastatic uveal melanoma (OptimUM-10)

Check if I qualify

Extracted eligibility criteria

Cancer type

Melanoma

Performance status

ECOG 0–1(Restricted strenuous activity)

Prior therapy

No prior treatment (treatment-naive required)

Max 0 prior lines

Cannot have received: any prior treatment for uveal melanoma

Previous treatment for UM

Lab requirements

Blood counts

Kidney function

Liver function

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

Mayo Clinic Scottsdale - PPDS · Scottsdale, Arizona
UCSD Moores Cancer Center · La Jolla, California
Jules Stein Eye Institute · Los Angeles, California
University of California Irvine Medical Center · Orange, California
Stanford Comprehensive Cancer Center · Palo Alto, California

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify